Evidence map›Paper›PMID 41103816›Full record

ArticleOrganelle (Tucson, Ariz.)2025

Organelle abnormalities in Alzheimer's disease.

Ju Gao, Lauren Vicuna, Xinglong Wang

Abstract read
In one paragraph

Article in Organelle (Tucson, Ariz.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ju GaoDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Lauren VicunaDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Xinglong WangDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.

Funding

Tailor-Made Molecular Chaperones to Target Protein MisfoldingR01AG082969 · NIA · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Shu-ou Shan, Xinglong Wang · 2023 to 2026
$2.1M
TDP-43 LLPS and mitochondrial dysfunction in neurodegenerationR01AG087952 · NIA · UNIVERSITY OF ARIZONA · PI Xinglong Wang · 2025 to 2026
$1.3M
Mitochondrial modulation of neuroinflammation in AD and related tauopathiesR01AG065342 · NIA · UNIVERSITY OF ARIZONA · PI Xinglong Wang · 2025 to 2026
$1.1M
FAM222A and amyloid plaque deposition in Alzheimer's DiseaseR01AG066578 · NIA · UNIVERSITY OF ARIZONA · PI WANG, XINGLONG · 2025 to 2025
$680k
NIA NIH HHS R01 AG065342NIA NIH HHS R01 AG066578NIA NIH HHS R01 AG082969NIA NIH HHS R01 AG087952
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common cause of dementia, pathologically characterized by extracellular amyloid plaques and intracellular neurofibrillary tangles. While these pathological hallmarks remain central to our understanding of AD, they do not fully explain the complex cellular failures observed throughout the disease course. Neurons are highly specialized and polarized cells that depend on an integrated and dynamic network of specialized subcellular compartments named organelles to maintain structure, metabolism, and communication. Given these critical roles, organelle dysfunction is increasingly recognized as a key contributor to AD pathogenesis. Structural and functional impairments in conventional organelles, including mitochondria, endoplasmic reticulum (ER), lysosomes, Golgi apparatus, and peroxisomes, are consistently observed in AD brains and experimental models. These impairments are believed to cause energy failure, disrupted proteostasis, intracellular trafficking defects, and elevated oxidative and ER stress. In parallel, abnormalities in membraneless organelles (MLOs) further compromise RNA regulation, protein synthesis, and cellular stress responses. Additionally, perturbed communication between organelles, such as at mitochondria-associated ER membranes (MAMs), lipid droplets, and primary cilia, further exacerbates signaling imbalances and neuronal vulnerability. In this review, we not only provide a comprehensive overview of abnormalities in both membrane-bound and membraneless organelles in AD, emphasizing how their dysfunction contributes to cellular stress, impaired homeostasis, and neurodegeneration, but also discuss how disruptions in organelles intersect with amyloid, tau, and other AD-associated pathologies to intensify disease progression. A deeper understanding of organelle dysfunction in AD may provide new mechanism insights and advance the development of effective disease modifying interventions.

Indexed as

Alzheimer’s diseaseamyloid plaquesendoplasmic reticulum stressliquid-liquid phase separationmembraneless organellesmitochondriaorganelle dysfunctiontau pathology

Identifiers

PMID41103816
PMCPMC12523919

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.